A polyvalent virosomal infuenza vaccine induces broad cellular and humoral immunity in pigs.

Detalhes bibliográficos
Autor(a) principal: HAACH, V.
Data de Publicação: 2023
Outros Autores: BASTOS, A. P. A., GAVA, D., FONSECA, F. M. da, MORES, M. A. Z., COLDEBELLA, A., FRANCO, A. C., SCHAEFER, R.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da EMBRAPA (Repository Open Access to Scientific Information from EMBRAPA - Alice)
Texto Completo: http://www.alice.cnptia.embrapa.br/alice/handle/doc/1156557
https://doi.org/10.1186/s12985-023-02153-5
Resumo: Abstract: Background: Influenza A virus (IAV) is endemic in pigs globally and co-circulation of genetically and antigenically diverse virus lineages of subtypes H1N1, H1N2 and H3N2 is a challenge for the development of effective vaccines. Virosomes are virus-like particles that mimic virus infection and have proven to be a successful vaccine platform against several animal and human viruses. Methods: This study evaluated the immunogenicity of a virosome-based influenza vaccine containing the surface glycoproteins of H1N1 pandemic, H1N2 and H3N2 in pigs. Results: A robust humoral and cellular immune response was induced against the three IAV subtypes in pigs after two vaccine doses. The influenza virosome vaccine elicited hemagglutinin-specific antibodies and virus-neutralizing activity. Furthermore, it induced a significant maturation of macrophages, and proliferation of B lymphocytes, effector and central memory CD4+ and CD8+ T cells, and CD8+ T lymphocytes producing interferon-γ. Also, the vaccine demonstrated potential to confer long-lasting immunity until the market age of pigs and proved to be safe and non-cytotoxic to pigs. Conclusions: This virosome platform allows flexibility to adjust the vaccine content to reflect the diversity of circulating IAVs in swine in Brazil. The vaccination of pigs may reduce the impact of the disease on swine production and the risk of swine-to-human transmission.
id EMBR_be77a5239770989f89fa51e0e4335d28
oai_identifier_str oai:www.alice.cnptia.embrapa.br:doc/1156557
network_acronym_str EMBR
network_name_str Repositório Institucional da EMBRAPA (Repository Open Access to Scientific Information from EMBRAPA - Alice)
repository_id_str 2154
spelling A polyvalent virosomal infuenza vaccine induces broad cellular and humoral immunity in pigs.Virosomal vaccineCellular immunitySuínoVacinaImunidadeSwineHumoral immunityInfluenza A virusAbstract: Background: Influenza A virus (IAV) is endemic in pigs globally and co-circulation of genetically and antigenically diverse virus lineages of subtypes H1N1, H1N2 and H3N2 is a challenge for the development of effective vaccines. Virosomes are virus-like particles that mimic virus infection and have proven to be a successful vaccine platform against several animal and human viruses. Methods: This study evaluated the immunogenicity of a virosome-based influenza vaccine containing the surface glycoproteins of H1N1 pandemic, H1N2 and H3N2 in pigs. Results: A robust humoral and cellular immune response was induced against the three IAV subtypes in pigs after two vaccine doses. The influenza virosome vaccine elicited hemagglutinin-specific antibodies and virus-neutralizing activity. Furthermore, it induced a significant maturation of macrophages, and proliferation of B lymphocytes, effector and central memory CD4+ and CD8+ T cells, and CD8+ T lymphocytes producing interferon-γ. Also, the vaccine demonstrated potential to confer long-lasting immunity until the market age of pigs and proved to be safe and non-cytotoxic to pigs. Conclusions: This virosome platform allows flexibility to adjust the vaccine content to reflect the diversity of circulating IAVs in swine in Brazil. The vaccination of pigs may reduce the impact of the disease on swine production and the risk of swine-to-human transmission.VANESSA HAACH, Universidade Federal do Rio Grande do Sul; ANA PAULA ALMEIDA BASTOS, CNPSA; DANIELLE GAVA, CNPSA; FRANCISCO NOE DA FONSECA, GEM; MARCOS ANTONIO ZANELLA MORES, CNPSA; ARLEI COLDEBELLA, CNPSA; ANA CLÁUDIA FRANCO, Universidade Federal do Rio Grande do Sul; REJANE SCHAEFER, CNPSA.HAACH, V.BASTOS, A. P. A.GAVA, D.FONSECA, F. M. daMORES, M. A. Z.COLDEBELLA, A.FRANCO, A. C.SCHAEFER, R.2023-09-11T12:24:50Z2023-09-11T12:24:50Z2023-09-112023info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleVirology Journal, v. 20, article number 181, 2023.http://www.alice.cnptia.embrapa.br/alice/handle/doc/1156557https://doi.org/10.1186/s12985-023-02153-5enginfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da EMBRAPA (Repository Open Access to Scientific Information from EMBRAPA - Alice)instname:Empresa Brasileira de Pesquisa Agropecuária (Embrapa)instacron:EMBRAPA2023-09-11T12:24:50Zoai:www.alice.cnptia.embrapa.br:doc/1156557Repositório InstitucionalPUBhttps://www.alice.cnptia.embrapa.br/oai/requestopendoar:21542023-09-11T12:24:50falseRepositório InstitucionalPUBhttps://www.alice.cnptia.embrapa.br/oai/requestcg-riaa@embrapa.bropendoar:21542023-09-11T12:24:50Repositório Institucional da EMBRAPA (Repository Open Access to Scientific Information from EMBRAPA - Alice) - Empresa Brasileira de Pesquisa Agropecuária (Embrapa)false
dc.title.none.fl_str_mv A polyvalent virosomal infuenza vaccine induces broad cellular and humoral immunity in pigs.
title A polyvalent virosomal infuenza vaccine induces broad cellular and humoral immunity in pigs.
spellingShingle A polyvalent virosomal infuenza vaccine induces broad cellular and humoral immunity in pigs.
HAACH, V.
Virosomal vaccine
Cellular immunity
Suíno
Vacina
Imunidade
Swine
Humoral immunity
Influenza A virus
title_short A polyvalent virosomal infuenza vaccine induces broad cellular and humoral immunity in pigs.
title_full A polyvalent virosomal infuenza vaccine induces broad cellular and humoral immunity in pigs.
title_fullStr A polyvalent virosomal infuenza vaccine induces broad cellular and humoral immunity in pigs.
title_full_unstemmed A polyvalent virosomal infuenza vaccine induces broad cellular and humoral immunity in pigs.
title_sort A polyvalent virosomal infuenza vaccine induces broad cellular and humoral immunity in pigs.
author HAACH, V.
author_facet HAACH, V.
BASTOS, A. P. A.
GAVA, D.
FONSECA, F. M. da
MORES, M. A. Z.
COLDEBELLA, A.
FRANCO, A. C.
SCHAEFER, R.
author_role author
author2 BASTOS, A. P. A.
GAVA, D.
FONSECA, F. M. da
MORES, M. A. Z.
COLDEBELLA, A.
FRANCO, A. C.
SCHAEFER, R.
author2_role author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv VANESSA HAACH, Universidade Federal do Rio Grande do Sul; ANA PAULA ALMEIDA BASTOS, CNPSA; DANIELLE GAVA, CNPSA; FRANCISCO NOE DA FONSECA, GEM; MARCOS ANTONIO ZANELLA MORES, CNPSA; ARLEI COLDEBELLA, CNPSA; ANA CLÁUDIA FRANCO, Universidade Federal do Rio Grande do Sul; REJANE SCHAEFER, CNPSA.
dc.contributor.author.fl_str_mv HAACH, V.
BASTOS, A. P. A.
GAVA, D.
FONSECA, F. M. da
MORES, M. A. Z.
COLDEBELLA, A.
FRANCO, A. C.
SCHAEFER, R.
dc.subject.por.fl_str_mv Virosomal vaccine
Cellular immunity
Suíno
Vacina
Imunidade
Swine
Humoral immunity
Influenza A virus
topic Virosomal vaccine
Cellular immunity
Suíno
Vacina
Imunidade
Swine
Humoral immunity
Influenza A virus
description Abstract: Background: Influenza A virus (IAV) is endemic in pigs globally and co-circulation of genetically and antigenically diverse virus lineages of subtypes H1N1, H1N2 and H3N2 is a challenge for the development of effective vaccines. Virosomes are virus-like particles that mimic virus infection and have proven to be a successful vaccine platform against several animal and human viruses. Methods: This study evaluated the immunogenicity of a virosome-based influenza vaccine containing the surface glycoproteins of H1N1 pandemic, H1N2 and H3N2 in pigs. Results: A robust humoral and cellular immune response was induced against the three IAV subtypes in pigs after two vaccine doses. The influenza virosome vaccine elicited hemagglutinin-specific antibodies and virus-neutralizing activity. Furthermore, it induced a significant maturation of macrophages, and proliferation of B lymphocytes, effector and central memory CD4+ and CD8+ T cells, and CD8+ T lymphocytes producing interferon-γ. Also, the vaccine demonstrated potential to confer long-lasting immunity until the market age of pigs and proved to be safe and non-cytotoxic to pigs. Conclusions: This virosome platform allows flexibility to adjust the vaccine content to reflect the diversity of circulating IAVs in swine in Brazil. The vaccination of pigs may reduce the impact of the disease on swine production and the risk of swine-to-human transmission.
publishDate 2023
dc.date.none.fl_str_mv 2023-09-11T12:24:50Z
2023-09-11T12:24:50Z
2023-09-11
2023
dc.type.driver.fl_str_mv info:eu-repo/semantics/publishedVersion
info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv Virology Journal, v. 20, article number 181, 2023.
http://www.alice.cnptia.embrapa.br/alice/handle/doc/1156557
https://doi.org/10.1186/s12985-023-02153-5
identifier_str_mv Virology Journal, v. 20, article number 181, 2023.
url http://www.alice.cnptia.embrapa.br/alice/handle/doc/1156557
https://doi.org/10.1186/s12985-023-02153-5
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.source.none.fl_str_mv reponame:Repositório Institucional da EMBRAPA (Repository Open Access to Scientific Information from EMBRAPA - Alice)
instname:Empresa Brasileira de Pesquisa Agropecuária (Embrapa)
instacron:EMBRAPA
instname_str Empresa Brasileira de Pesquisa Agropecuária (Embrapa)
instacron_str EMBRAPA
institution EMBRAPA
reponame_str Repositório Institucional da EMBRAPA (Repository Open Access to Scientific Information from EMBRAPA - Alice)
collection Repositório Institucional da EMBRAPA (Repository Open Access to Scientific Information from EMBRAPA - Alice)
repository.name.fl_str_mv Repositório Institucional da EMBRAPA (Repository Open Access to Scientific Information from EMBRAPA - Alice) - Empresa Brasileira de Pesquisa Agropecuária (Embrapa)
repository.mail.fl_str_mv cg-riaa@embrapa.br
_version_ 1794503549147676672